purple-logo2020.png
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
July 10, 2024 07:30 ET | Purple Biotech Ltd.
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies...
purple-logo2020.png
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
June 27, 2024 07:45 ET | Purple Biotech Ltd.
New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV...
Immuneering-logo (1).png
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024 08:00 ET | Immuneering Corporation
– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase...
purple-logo2020.png
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023 06:50 ET | Purple Biotech Ltd.
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple...
purple-logo2020.png
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023 08:00 ET | Purple Biotech Ltd.
REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
purple-logo2020.png
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023 08:15 ET | Purple Biotech Ltd.
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Qualigen-Logo-Tag.png
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 02, 2023 08:15 ET | Qualigen Therapeutics, Inc.
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
1
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
April 18, 2023 08:45 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen-Logo-Tag.png
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
March 21, 2023 08:35 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
March 15, 2023 09:05 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...